USE OF MIDODRINE TO DECREASE HOSPITALIZATION LENGTH IN END-STAGE HEART FAILURE

Autor:	Marcel Mesa Pabon, Ariel F. Gonzalez, Hilton Franqui-Rivera
Rok vydání:	2020
Předmět:	medicine.medical_specialty business.industry Public health Midodrine Disease medicine.disease Refractory Heart failure medicine End stage heart failure Cardiology and Cardiovascular Medicine Intensive care medicine business Medical therapy medicine.drug
Zdroj:	Journal of the American College of Cardiology. 75:2583
ISSN:	0735-1097
DOI:	10.1016/s0735-1097(20)33210-1
Popis:	Heart failure (HF) has been termed a global public health burden, with a prevalence of 23 million cases worldwide. Approximately 5% of patients with heart failure progress to end-stage disease refractory to medical therapy. Often these patients do not qualify for a heart transplant or left the
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5766a5d804c8dfa0a28b5c9cc61406bf https://doi.org/10.1016/s0735-1097(20)33210-1 Zobrazit plný text záznamu